Showing results 1 to 1 of 1
Issue Date | Title | Journal Title |
---|---|---|
2022 | Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study | ANNALS OF ONCOLOGY |